Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Di | SunLink Health Systems GAAP EPS of -$0.09, revenue of $7.32M | 1 | Seeking Alpha | ||
Di | SUNLINK HEALTH SYSTEMS INC - 10-Q, Quarterly Report | 1 | SEC Filings | ||
15.04. | SUNLINK HEALTH SYSTEMS INC - 8-K, Current Report | 1 | SEC Filings | ||
15.04. | Regional Health Properties, Inc.: Regional Health Properties And Sunlink Health Systems Revise All-stock Merger Transaction | 124 | GlobeNewswire (Europe) | Atlanta, GA, April 15, 2025 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. ("Regional") (OTCQB: RHEP) (OTCQB: RHEPA) and SunLink Health Systems, Inc. ("SunLink") (NYSE American: SSY) jointly... ► Artikel lesen | |
12.02. | SunLink Health Systems GAAP EPS of -$0.19, revenue of $7.93M | 1 | Seeking Alpha | ||
12.02. | SunLink Health Systems, Inc. Announces Fiscal 2025 Second Quarter Results | 75 | Business Wire | ATLANTA--(BUSINESS WIRE)--SunLink Health Systems, Inc. (NYSE American: SSY) today announced a loss from continuing operations of $1,070,000 (or a loss of $0.15 per fully diluted share) for its... ► Artikel lesen | |
12.02. | SUNLINK HEALTH SYSTEMS INC - 10-Q, Quarterly Report | - | SEC Filings | ||
SUNLINK HEALTH SYSTEMS Aktie jetzt für 0€ handeln | |||||
06.01. | SUNLINK HEALTH SYSTEMS INC - 8-K, Current Report | 1 | SEC Filings | ||
06.01. | SunLink Health Joins Forces With Regional Health Properties In All-Stock Deal: Shares Surge | 1 | Benzinga.com | ||
06.01. | Regional Health Properties to acquire SunLink Health in an all-stock deal | 5 | Seeking Alpha | ||
06.01. | Regional Health Properties, Inc.: Regional Health Properties And Sunlink Health Systems To Merge In An All-stock Transaction | 164 | GlobeNewswire (Europe) | Enhances Opportunity to Increase Shareholder Value Significantly Strengthens Balance Sheet Expands Regional Board with the Addition of Two Highly Qualified Industry Veterans Atlanta, GA, Jan. 06,... ► Artikel lesen | |
12.11.24 | SunLink Health Systems, Inc. Announces Fiscal 2025 First Quarter Results | 106 | Business Wire | ATLANTA--(BUSINESS WIRE)--SunLink Health Systems, Inc. (NYSE American: SSY) today announced a loss from continuing operations of $442,000 (or a loss of $0.06 per fully diluted share) for its first... ► Artikel lesen | |
01.10.24 | SunLink Health Systems, Inc. Announces Fiscal 2024 Fourth Quarter and Annual Results | 134 | Business Wire | ATLANTA--(BUSINESS WIRE)--SunLink Health Systems, Inc. (NYSE American: SSY) today announced a loss from continuing operations of $652,000 (or a loss of $0.09 per fully diluted share) for its fourth... ► Artikel lesen | |
15.05.24 | SunLink Health Systems, Inc. Announces Fiscal 2024 Third Quarter Results | 161 | Business Wire | ATLANTA--(BUSINESS WIRE)--SunLink Health Systems, Inc. (NYSE American: SSY) today announced a loss from continuing operations of $824,000 (or a loss of $0.12 per fully diluted share) for its third... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SERNOVA BIOTHERAPEUTICS | 0,129 | -5,15 % | Sernova Biotherapeutics Inc: Sernova talks interim data from Cell Pouch trial | ||
ATOSSA THERAPEUTICS | 0,905 | +16,32 % | Atossa Therapeutics Inc: Atossa Therapeutics Announces Full Results from I-SPY 2 Endocrine-Optimization Sub-Study Evaluating Low-Dose (Z)-Endoxifen | Feasibility endpoint achieved; rapid Ki-67 suppression and substantial MRI-confirmed tumor shrinkage observed with favorable safety profile
SEATTLE, May 14, 2025 /PRNewswire/ -- Atossa Therapeutics... ► Artikel lesen | |
PING AN HEALTHCARE | 0,802 | 0,00 % | Ping An Healthcare and Technology Company Limited: Ping An Health Reports 25.8% Year-on-Year Revenue Growth in Q1 2025, with Profitability Accelerating | Revenue and Profit Surge, Driven by "AI + Health Care" Value Empowerment
SHANGHAI and HONG KONG, April 24, 2025 /PRNewswire/ -- Ping An Healthcare and Technology... ► Artikel lesen | |
MOUNTAIN VALLEY MD | 0,015 | 0,00 % | Mountain Valley MD Holdings Inc: Mountain Valley hopes for continued growth in 2025 | ||
CO-DIAGNOSTICS | 0,244 | -21,29 % | Co-Diagnostics GAAP EPS of -$0.24 beats by $0.03, revenue of $0.05M misses by $0.14M | ||
CYTOSORBENTS | 0,697 | -6,82 % | Cytosorbents Corp: CytoSorbents Reports First Quarter 2025 Financial Results and Provides Business Update | PRINCETON, N.J., May 14, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive... ► Artikel lesen | |
VERU | 0,450 | -0,49 % | JTC Team, LLC: JTC Team Hosts Virtual Investor "KOL Connect" Segment to Discuss Veru Inc.'s Enobosarm Taking GLP-1 Weight Loss to Next Level | Moderated discussion with preeminent obesity expert Louis J. Aronne, MD, FACP and Mitchell Steiner, M.D., F.A.C.S, President, CEO, and Founder of Veru Watch the "KOL Connect" segment here FRENCHTOWN... ► Artikel lesen | |
TEMPEST THERAPEUTICS | 7,050 | -100,00 % | Tempest Therapeutics: Tempest Reports First Quarter 2025 Financial Results and Provides Business Update | Presented new amezalpat mechanism-of-action data reinforcing its potential as a novel cancer treatment at the 2025 AACR Annual MeetingGranted Orphan Drug designation by FDA for TPST-1495 for the treatment... ► Artikel lesen | |
VOLITIONRX | 0,465 | -2,52 % | VolitionRX Q1 2025 Earnings Preview | ||
EKSO BIONICS | 0,388 | -3,00 % | Ekso Bionics Holdings, Inc.: Ekso Bionics Accepted into NVIDIA Connect Program | ||
IMUNON | 0,540 | -1,82 % | Imunon, Inc.: IMUNON Announces Six-Month Data Showing Durability of Protection for Next-Generation DNA Vaccine Platform in Phase 1 Clinical Trial in COVID-19 | Company's PlaCCine® technology platform demonstrates better durability and other advantages compared to mRNA vaccines Results further validate PlaCCine as a novel vaccine platform with potential applications... ► Artikel lesen | |
BEYOND AIR | 0,170 | +3,03 % | Beyond Air: NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism | The FDA designation marks a significant milestone in the development of a novel treatment for a rare neurodevelopmental disorder Plan to initiate first-in-human U.S. clinical trials of lead drug candidate... ► Artikel lesen | |
AVINGER | 0,340 | -6,08 % | Avinger Inc - 8-K, Current Report | ||
NOVACYT | 0,469 | +0,11 % | Novacyt announces AGM scheduled for June 19, 2025 | ||
AROVELLA THERAPEUTICS | 0,042 | 0,00 % | Biocurious: With its 'molecular Lego' approach, Arovella is building hope for cancer patients one brick at a time |